Murray IR, Makaram NS, Geeslin AG, Chahla J, Moatshe G, Crossley K, Kew ME, Davis A, Tuca M, Potter H, Janse van Rensburg DC, Emery CA, Eun S, Grindem H, Noyes FR, Marx RG, Harner C, Levy BA, King E, Cook JL, Whelan DB, Hatch GF 3rd, Wahl CJ, Thorborg K, Irrgang JJ, Pujol N, Medvecky MJ, Stuart MJ, Krych AJ, Engebretsen L, Stannard JP, MacDonald P, Seil R, Fanelli GC, Maak TG, Shelbourne KD, Verhagen E, Musahl V, Hirschmann MT, Miller MD, Schenck RC, and LaPrade RF
Multiligament knee injuries (MLKIs) represent a broad spectrum of pathology with potentially devastating consequences. Currently, disagreement in the terminology, diagnosis and treatment of these injuries limits clinical care and research. This study aimed to develop consensus on the nomenclature, diagnosis, treatment and rehabilitation strategies for patients with MLKI, while identifying important research priorities for further study. An international consensus process was conducted using validated Delphi methodology in line with British Journal of Sports Medicine guidelines. A multidisciplinary panel of 39 members from 14 countries, completed 3 rounds of online surveys exploring aspects of nomenclature, diagnosis, treatment, rehabilitation and future research priorities. Levels of agreement (LoA) with each statement were rated anonymously on a 5-point Likert scale, with experts encouraged to suggest modifications or additional statements. LoA for consensus in the final round were defined 'a priori' if >75% of respondents agreed and fewer than 10% disagreed, and dissenting viewpoints were recorded and discussed. After three Delphi rounds, 50 items (92.6%) reached consensus. Key statements that reached consensus within nomenclature included a clear definition for MLKI (LoA 97.4%) and the need for an updated MLKI classification system that classifies injury mechanism, extent of non-ligamentous structures injured and the presence or absence of dislocation. Within diagnosis, consensus was reached that there should be a low threshold for assessment with CT angiography for MLKI within a high-energy context and for certain injury patterns including bicruciate and PLC injuries (LoA 89.7%). The value of stress radiography or intraoperative fluoroscopy also reached consensus (LoA 89.7%). Within treatment, it was generally agreed that existing literature generally favours operative management of MLKI, particularly for young patients (LoA 100%), and that single-stage surgery should be performed whenever possible (LoA 92.3%). This consensus statement will facilitate clinical communication in MLKI, the care of these patients and future research within MLKI., Competing Interests: ompeting interests: IRM reports the following disclosures: Arthrex: paid consultant; Bone and Joint Research: editorial or governing board; Journal of Bone and Joint Surgery—British: editorial or governing board; Stryker: paid consultant. AG reports the following disclosures: American Orthopaedic Society for Sports Medicine: board or committee member; Arthroscopy: editorial or governing board, Infographics Editor; Ossur: paid presenter or speaker; Smith & Nephew: paid consultant; paid presenter or speaker. JC reports the following disclosures: American Orthopaedic Society for Sports Medicine: board or committee member; Arthrex: paid consultant; Arthroscopy Association of North America: board or committee member; Conmed Linvatec: paid consultant; International Society of Arthroscopy, Knee Surgery, and Orthopaedic Sports Medicine: board or committee member; Ossur: paid consultant; Smith & Nephew: paid consultant. GM reports the following disclosures: Smith & Nephew: paid consultant; IBSA: paid consultant; International Society of Arthroscopy, Knee Surgery, and Orthopaedic Sports Medicine: board or committee member; Arthroscopy: editorial board; JBJS: editorial board. RFLP reports the following disclosures: American Journal of Sports Medicine: editorial or governing board; American Orthopaedic Society for Sports Medicine: board or committee member; Arthrex: IP royalties; International Society of Arthroscopy, Knee Surgery, and Orthopaedic Sports Medicine: board or committee member; Journal of Experimental Orthopaedics: editorial or governing board; Knee Surgery, Sports Traumatology, Arthroscopy: editorial or governing board; Ossur: IP royalties, paid consultant, research support; Smith & Nephew: IP royalties, paid consultant; research support; Journal of Knee Surgery: editorial or governing board; Orthopaedic Techniques in Sports Medicine: editorial or governing board. JJI reports the following disclosures: receives funding as PI from Department of Defense Congressionally Directed Medical Research Programme Peer Reviewed Orthopaedic Research Programme for the Surgical Timing and Rehabilitation (STaR) Trial for Multiple Ligament Knee Injuries (MLKIs): A Multicenter Integrated Clinical Trial (W81XWH-17-2-0073) and serves as President, Board of Directors for Movement Science Media/Journal of Orthopaedic and Sports Physical Therapy. GM reports the following disclosures: Smith & Nephew, IBSA: consultant; ISAKOS: committee member; JBJS and arthroscopy: editorial board; Smith & Nephew: fellowship funding. GFH III reports the following disclosures: Arthrex: consultant. MS reports the following disclosures: Arthrex: consultant and royalties; Stryker, USA Hockey Foundation: research funding; MEK reports the following disclosures: AANA: research committee; AOSSM: enduring education committee; Arthrex; Smith & Nephew: education funds; PMacD reports the following disclosures: Arthrex and Conmed: consultant; Arthrex, Conmed, Zimmer Biomet, Smith & Nephew, Ossur: research and fellowship support; KMC reports the following disclosures: BJSM: senior advisor. BL reports the following disclosures: Arthrex: consultant and royalties; JKS and KSSTA: editorial board; MJM reports the following disclosures: Smith & Nephew: paid speaker. KT reports the following disclosure: Deputy Editor: BJSM. TGM reports the following disclosures: Arthrex: speaker, consultant; CORR: editorial board. EV reports the following disclosures: Associate Editor: BJSM; Editor-in-Chief: BMJ Open SEM. AJK reports the following disclosures: Arthrex: consultant, IP royalties; JRF Orthopaedics, Vericel, Responsive Arthroscopy: consulting fees; DJO: grants; Musculoskeletal Transplant Foundation: board of trustees. RCS reports the following disclosures: Arthrex: education; Editorial Board: AJSM and JBJS. JPS reports the following disclosures: Thieme: Publishing Royalties; DePuy: consulting fees/teaching courses; Arthrex: consulting fees/teaching courses; AO NA: research support, teaching and travel support; AO Foundation: teaching/travel support; Journal of Knee Surgery: Editor-in-Chief. CE reports the following disclosures: Canadian Institutes of Health Research, Canada Foundation for Innovation, Canada Research Chairs Programme and National Football League Play Smart Play Safe Programme: peer-reviewed research support; Associate Editor: BJSM; External Advisory Board: HitIQ Chairperson: Sport Injury Prevention Research Centre, an IOC Research Centre for Prevention of Injury and Protection of Athlete Health. HG reports the following disclosures: Associate Editor: BJSM, JOSPT. RGM reports the following disclosures: Mend nutrition. Royalties from Springer and Demos for books. JLC reports the following disclosures: AANA: research support; AO Trauma: research support; Arthrex: IP royalties; paid consultant; research support; Bioventus: paid consultant; Boehringer Ingelheim: paid consultant; Collagen Matrix: paid consultant; research support; GE Healthcare: research support; Journal of Knee Surgery: editorial or governing board; Midwest Transplant Network: board or committee member; Musculoskeletal Transplant Foundation: board or committee member; IP royalties; research support; National Institutes of Health (NIAMS & NICHD): research support; OREF: research support; Orthopaedic Trauma Association: research support; PCORI: research support; Regenosine: research support; SITES Medical: research support; Thieme: publishing royalties, financial or material support; Trupanion: paid consultant. VM reports the following disclosures: Smith & Nephew, Newclip: consultant; Ostesys: Shareholder; Arthrex, Smith & Nephew: educational grants; ISAKOS: board or committee member; KSSTA: Deputy Editor-in-Chief. MTH reports the following disclosures: Knee Surgery Sports Traumatology Arthroscopy (KSSTA): Deputy Editor-in-Chief; APKASS journal, MLT journal, Arthroskopie, Das Knie (DKG): board or committee member; European Knee Associates (EKA): Past Chairman; ESSKA Milan 2020 and 2021: Scientific Chairman; ISAKOS: Arthroplasty Committee; ESSKA: Cartilage Committee; German Knee Society: board or committee member; Personalized Arthroplasty Society (PAS): 2nd vice president DepuySynthes, Smith & Nephew, Symbios, Medacta: cconsultant; DepuySynthes, Finceramica, Symbios, Mathys, Arthrex, SIWF, Deutsche Arthrose-Hilfe, Bangerter-Rhyner-Stiftung: research grants. NM, HP, SPE, KDS, CJW, FRN, MT, DCCJvR, EK, DBW, MDM, GCF, CH, LE, RS and NP report no competing interests., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)